Investigational glucagon-like peptide-1 agonists for the treatment of obesity
The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
INTRODUCTION: Obesity is a worldwide problem predisposing to type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, cancer and other comorbidities. Lifestyle modification is the first line intervention but adjunctive pharmacotherapy is often required. The GLP-1 receptor agonists (GLP-1RAs) were developed primarily for T2DM and they also reduce body weight. Liraglutide was approved for the treatment of obesity and other GLP-1RAs are likely to be suitable for this indication. AREAS COVERED: This review describes the GLP-1RAs that have been approved for the treatment of T2DM as potential candidates for the treatment of obesity and the new agents currently under development which may have advantages in patient adherence. EXPERT OPINION: The GLP-1RAs offer a welcome addition to obesity pharmacotherapy. They appear to be free of serious adverse effects although uncertainty remains about possible risks of pancreatitis and neoplasms. However, they have frequent gastrointestinal side effects, particularly nausea, which limits their tolerability. Cardiovascular outcome studies in T2DM support their use and this is likely to increase in both T2DM and obesity. Other GLP-1RAs which can be given by subcutaneous injection once weekly or less frequently or by oral administration would have advantages especially if nausea is less frequent than with liraglutide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the trials, GI symptoms rarely led to discontinuation, with <10% of participants stopping therapy due to GI issues [49].”
In the citing paper
“In the trials, GI symptoms rarely led to discontinuation, with <10 % of participants stopping therapy due to GI issues [47].”
In the citing paper
“In the trials, GI symptoms rarely led to discontinuation, with <10% of participants stopping therapy due to GI issues [49].”
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“8 mg daily compared to placebo in 9340 high-CV-risk T2DM patients [124].”
BackgroundMechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 1×
“diabetes mellitus (T2DM) [3] and contributes substantially to the development of hypertension and some cancers [4].”
BackgroundDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 3×
“The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) study was the first CV outcome study with a GLP-1RA to be completed [73].”
BackgroundInfluential
Research works printed but not linked: 2
- Baron MA, Buse J, Azeem R, et al. A randomised, double-blind, placebo-controlled, 39 week trial of ITCA 650 as add-on therapy in type 2 diabetes. Diabetologia. 2015;58:S55–S55.
- Henry RR, Rosenstock J, Denham D, et al. Efficacy and tolerability of ITCA 650 (continuous subcutaneous exenatide) for 39 weeks in patients with poorly controlled type 2 diabetes mellitus and high baseline HbA(1c) (>10%). Diabetologia. 2015;58:S378.
Cited by
Targeting autophagy in obesity: from pathophysiology to management
Zhang, Y., Sowers, J. R., & Ren, J. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0009-1 · Cited by 338
Self-citationObesity and cancer: existing and new hypotheses for a causal connection
Stone, T. W., McPherson, M., & Gail Darlington, L. (2018) · eBioMedicine · doi:10.1016/j.ebiom.2018.02.022 · Cited by 262
“The prominent link between inflammation and obesity has been further emphasized byfinding that theNLRP3 inflammasomemay contribute to the pathology (Stienstra et al., 2010; Vandanmagsar et al., 2011).”
BackgroundMulti-Target Approaches in Metabolic Syndrome
Lillich, F. F., Imig, J. D., & Proschak, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.554961 · Cited by 178
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“In the trials, GI symptoms rarely led to discontinuation, with < 10 % of participants stopping therapy due to GI issues [47].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
Metadata
- Authors
- Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M.
- Affiliations
- Tongji University (CN)
- Chinese University of Hong Kong (HK)
- Wan Fang Hospital (TW)
- Corresponding author
- Tomlinson, Brian
- Chan, Paul
- Liu, Zhong-Min
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2016-08-26
- Volume
- 25
- Issue
- 10
- Pages
- 1167-1179
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2508533215
- Cited by
- 25
- References
- 104
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 2 · 2023: 1 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 4 · 2016: 1
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity, GLP-1 receptor agonists, liraglutide, type 2 diabetes, obesity pharmacotherapy, weight loss, pancreatitis risk, neoplasms, nausea, gastrointestinal adverse effects, subcutaneous injection, patient adherence, cardiovascular outcomes
- MeSH terms
- Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Body Weight, Diabetes Mellitus, Type 2, Humans, Obesity, Drug Design, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Investigational glucagon-like peptide-1 agonists for the treatment of obesity. https://app.cochat.ai/papers/10.1080/13543784.2016.1221925
- The paper
- Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016). Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2016.1221925
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.